Determination of Visfatin Level in Patients with Diabetes and Peripheral Neuropathy as Early Predicted Factor
Main Article Content
Abstract
Peripheral neuropathy represents one of the common diabetic complications in patients with diabetes mellitus type 2 (DMT2). Peripheral neuropathy affects the feet, legs, hands, and arms. It was found that one-third to one-half of diabetics have peripheral neuropathy. The current study aimed to evaluate the level of visfatin in diabetic patient groups with or without peripheral neuropathy in comparison with healthy subjects to knowledge whether visfatin can be applied as a predictor factor for this type of disease complication. The study included 120 males and females ranging in age from 40 to 97 years old. (40 patients with type 2 diabetes, 40 patients with diabetic peripheral neuropathy, and 40 healthy people served as the control group.) All of the diabetes patients had a verified diagnosis (type 2). During the period from October 2021 to December 2021, the patients were assessed at the National Diabetes Center, Al-Mustansiriya University in Baghdad. Visfatin levels were tested using the ELISA technique, and HbA1c was assessed using Cobas C111. In patients, HbA1C levels are significantly higher (p≤0.05) than in controls. Males and females with DPN and DM have greater Visfatin mean values than the control group. Visfatin levels are strong indications for early diagnosis of diabetic neuropathy in both males and females, according to the current study.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
licenseTerms
Publication Dates
References
Zainab A. Salman; Kadhim K. Ghudhaib and Raghad Fadhil. Evaluating osteocalcin and ostenectin in serum male patients with type 2 diabetes mellitus and periodontitis.Eurasian Chemical Communications. 2022,4,295-302.
Zainab A. Salman; Kadhim K. Ghudhaib and Raghad Fadhil.. Association of osteopontin and alkaline phosphatase in male patients with diabetes mellitus type 2 and periodontitis. Iranian Journal of War and Public Health . 2022,14(1),105-109.
Reham Khuldon Ibrahim; Kadhim K. Ghudhaib and Ali Abdulmajid Dyab Allawi. Association of CTGF and TGF-β1 with glomerulus fibrosis in Iraqi diabetic patients with chronic kidney disease. Journal of Infection and Chemotherapy. 2022, 28 (10): accepted for publishing
Reham Khuldon Ibrahim; Kadhim K. Ghudhaib and Ali Abdulmajid Dyab Allawi. Evaluation of ATPase level in Iraqi diabetic patients with or without diabetic kidney disease. Journal of Process Biochemistry. Accepted for publishing in 2022, 121.
Ghada Salam Hamid. Ali A. Allawi; Kadhim K.Ghudhaib. Correlation of Pentosidine with Kidney Diseases in Iraqi Patients with Diabetic Nephropathy. Iraqi Journal Science.2021, 62(10):3436-3442.
Wahaj Sinan Mohammed; Kadhim K. Ghudhaib ; Ali A. Allawi. Evaluation of Glomerular Disorder in Diabetic Patients with Nephropathy. Biochemical and Cellular Archives. 2022,22 (1), 963-969.
Marwa Nazar; Kadhim, K. Ghudhaib ; Firas Y. Mohsen. Evaluation of Nerve Growth Factor, Fetuin A and Adiponectin Levels in Diabetic Patients with Sensory Neuropathy. Drugs and Cell Therapies in Hematology (Clarivate), 2021, 10(1),4103-4117.
Zina J. Ghaib; Kadhim K. Ghudhiab ; Firas Y. Mohsen. Assessment of Neuron Specific Enolase Level and some Related Biochemical Factors in Patients with Diabetic Peripheral Nerve Disorders. Indian Journal of Forensic Medicine & Toxicology. 2021,15 (3), 15 Issue 3, 1494-1500.
Kadhim K. Ghudhaib; Kismat M.Turaki ; Sabreen A. Muzal. Estimation of Serum Osteocalcin Levels in Osteoporotic Postmenopausal Women with Type 2 Diabetes Mellitus. Baghdad Sci. 2014, J. 11 (4):1549-1555.
Gnatiuc, Louisa; et al. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. The lancet Diabetes & endocrinology. 2018, 6,7, 538-546.
Pop-Busui R; Boulton, AJ; Feldman ,EL; et al. Diabetic neuropathy: a posi¬tion statement by the American Diabetes Association. Diabetes Care .2017,40,136–154.
Dabelea D; Stafford JM; Mayer-Davis EJ; et al.; SEARCH for Diabetes in Youth Research Group. Association of type 1 dia¬betes vs type 2 diabetes diagnosed during childhood and adolescence with compli¬cations during teenage years and young adulthood. JAMA.2017,317,825–835.
Selvarajah; Dinesh; SLOAN; Gordon; TESFAYE, Solomon. Diabetic Neuropathy. The Foot in Diabetes. 2020, 89-103.
Dewanjee; Saikat; et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. European journal of pharmacology.2018, 833, 472-523.
Carbone, F; Liberale, L; Bonaventura, A; Vecchie ,A; Casula M; Cea M; et al. Regulation and function of extracellular nicotinamide phosphoribosyltransferase/visfatin. Compr Physiol. 2017,7(2),603–21.
Yu PL; Wang, C.; Li W; Zhang, FX. Visfatin level and the risk of hypertension and cerebrovascular accident: a systematic review and meta-analysis. Horm Metab Res. 2019,51(4),220–9.
Auguet T.; Aragones, G.; Guiu-Jurado, E.; Berlanga, A.; Curriu, M.; Martinez, S.; et al. Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque. BMC Cardiovasc Disord. 2016,16(1),149.
Li B; Zhao Y.; Liu, H.; Meng ,B.; Wang J; Qi T; et al. Visfatin destabilizes atherosclerotic plaques in apolipoprotein E-deficient mice. PLoS ONE. 2016,11(2).
ZHENG; Long-Yi; et al. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetology & metabolic syndrome, 2019, 11,1,1-7.
Sapra, Amit; Priyanka Bhandari; and A. Wilhite Hughes. Diabetes Mellitus (Nursing) 2021 .
World Health Organization. Global Report on ddiabetes. Geneva, Switzerland. 2017.
Danaei; Goodarz; et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2• 7 million participants. The lancet,2011, 378,9785, 31-40.
Jende; Johann, ME.; et al. Association of serum cholesterol levels with peripheral nerve damage in patients with type 2 diabetes. JAMA network open, 2019, 2,5. e194798-e194798..
Gordon; Lorenzo; et al. Lipid profile of type 2 diabetic and hypertensive patients in the Jamaican population. Journal of laboratory physicians, 2010, 2,01, 025-030.
Sabahelkhier; Murwan Khalid; et al. A study of lipid profile Levels of Type II Diabetes Mellitus. Nova Journal of Medical and Biological Sciences, 2016, 5,2, 1-9.
Artha; I. Made Junior Rina; et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vascular Health and Risk Management .2019, 15 , 149.
Biradar; Satish Basanagouda; et al. Correlation between glycemic control markers and lipid profile in type 2 diabetes mellitus and impaired glucose tolerance. Int J Adv Med,2018, 23,5, 4.
Saha, Sayantaann, ; Roopa Murgod. Evaluation of iron profile in type II diabetes mellitus cases. International Journal of Biotechnology and Biochemistry.2019,15,1 , 27-37.
Neboh; Emeka E.; et al. Lipid Profile, Aip And Glycated Haemoglobin Level In Type-2 Diabetic Patients In Enugu, South-East Nigeria. Journal of Asian Scientific Research.2012, 2.5, 300-306.
Abdulkader; Rand Thair; Nada A. Kadhim, and Firas Younus Muhsin. The Association of Low Taurine Levels with Diabetic Neuropathy in Iraqi Patients. Indian Journal of Forensic Medicine & Toxicology . 2021,15.4.
Khursheed MU; Bikha RD; Syed ZA; Tarachand D; Thanwar D; Samar R; et al. Lipid Profile of Patients with Diabetes mellitus (A Multidisciplinary Study). World Applied Sciences Journal. 2011,12 (9),1382-1384.
Ahmed SE; Mustafa E; Mohamed AE. Assessment of Plasma Levels of Fasting Blood Glucose, Triglycerides, Total Cholesterol, and HbA1c in patients with Type 2 Diabetes Mellitus. International Journal of Health Sciences & Research. 2013, 3(9), 1-6.
Yassin M; Altibi H; El Shanti A. Clinical and biochemical features of type 2 diabetic patients in Gaza Governorate, Gaza Strip. West African Journal Medicine. 2011, 30(1), 51-56
Khan, HA.; Sobki, SH.; Khan, SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007,7,24–9
Romacho, Tania; Carlos F. Sánchez-Ferrer; and Concepción Peiró. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators of inflammation 2013 (2013).
Buyukaydin; Banu; et al. Relationship between diabetic polyneuropathy, serum visfatin, and oxidative stress biomarkers. World Journal of Diabetes . 2020,11,7, 309.
Alghasham; Abdullah, A.; Youssef, A. Barakat. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi medical journal . 2008,29,2 ,185-192.
Liang; Wei; and Dong dong Ye. The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus. Cytokine & growth factor reviews . 2019, 48 ,32-39.
Wang; Yongqiang; Ye Yuan; Hua Jiang. Serum and vitreous levels of visfatin in patients with diabetic retinopathy. Medical science monitor: international medical journal of experimental and clinical research . 2014, 20 , 2729.
Mageswari; Ramalingam; et al. Irisin and Visfatin Predicts Severity of Diabetic Nephropathy. Indian Journal of Clinical Biochemistry . 2019,34,3, 342-346.
Lee; Young Ho; Sang‐Cheol Bae. Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta‐analysis.International journal of rheumatic diseases. 2018,21,3 ,664-672.
Mousavi; Zohreh; et al. Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome. Medical journal of the Islamic Republic of Iran . 2017, 31 ,28.